**2022-RA-1358-ESGO** CLOUD-BASED WEB APPLICATION TO REDUCE DELAY IN CANCER TREATMENT

1Jack Le Bon, 1Kathryn Jones, 2Sadie Esme Fleur Jones, 1Cardiff University, Cardiff, UK; 2National Health Service, Cardiff, UK

10.1136/ijgc-2022-ESGO.995

**Introduction/Background** Gynaecological oncology departments host sophisticated clinical pathways that help guide ovarian cancer patients through their individual and tailored treatment plans. Departments within the UK’s National Health Service (NHS) have long endured using an in-house built spreadsheet to manage these complex ovarian cancer pathways. This ill-fitting system cannot effectively manage the intricate details nor enforce compliance with pathway policies; resulting in an unmanageable solution that impacts patients’ care and prognoses by causing significant increase in initial treatment wait-time, with examples exceeding a 160% increase from target.

**Methodology** To begin countering this widespread issue, users were interviewed to gain a deeper understanding of the complex clinical pathways. These requirement-gathering sessions were later leveraged to design a secure, scalable, and purpose-built cloud-based web application to rectify this issue. The User Experience (UX) design process involved requirement elicitation to create several use-cases and wireframes, leading towards a high-fidelity prototype using Amazon Web Services (AWS).

**Results** The result of this project is a feature-rich prototype that automatically enforces pathway compliance, and provides real-time notifications and data insights, while promptly distributing patient communication. The product leverages several cloud services, maintaining a low-cost and high-availability architecture; and has subsequently been embraced as a catalyst and foundation of future work by NHS expert users.

**Conclusion** This implementation is set to guide and influence a software development company to create a production-ready product, aiming to reduce the wait times that ovarian cancer patients experience, while also reducing the administrative workload of clinicians; providing a greater ability to focus on the things that matter most.

**2022-RA-1366-ESGO** IMPLEMENTATION OF DAY CASE MINIMAL ACCESS HYSSTERECTOMY

1Hannah Pierce, 1Cate Foschaw, 1Michelle Ann Louise Godfrey, 1Nataasha Victoria Craig, 1Sophie Stezaker, 1Francis Gardner, 2Obstetrics and Gynaecology, Queen Alexandra Hospital, Cosham, Portsmouth, UK; 2Gynaecological Oncology Department, Queen Alexandra Hospital, Cosham, Portsmouth, UK; 3Obstetrics and Gynaecology, Princess Anne Hospital, Southampton, UK

10.1136/ijgc-2022-ESGO.996

**Introduction/Background** Laparoscopic hysterectomy has been named a key procedure for improving day case rates in the Sept 2020 National Day Surgery Delivery pack – A collaborative document involving ‘Getting it right first time’, ‘Centre for pre-operative care’ and the ‘British Association of Day Surgery.’ The COVID pandemic, along with general winter pressures on availability of hospital beds led us to developing a new pathway for day-case minimal access hysterectomy. Our aim was to implement day-case minimal access hysterectomy in Queen Alexandra Hospital, Portsmouth and to audit the complication rates.

**Methodology** All suitable patients were offered day-case minimal access hysterectomy from 1st December 2020 and all patients discharged home the same day had the data prospectively collected to monitor potential complication rates. For comparison, complication data was collected from a cohort of patients admitted overnight for a minimal access hysterectomy from the surgeon (a gynaecological- oncology consultant) with the highest uptake in day-case hysterectomy.

**Results** From the 1st December 2020 to the 25th January 2022 28 patients went home on the day of their minimal access hysterectomy (20 were done by the same surgeon (Surgeon 1). In the same timeframe Surgeon 1 admitted 27 minimal access hysterectomies overnight. The complication rate for same day discharge was comparable, with no day-case hysterectomies re-presenting to hospital within the first 7 days post-surgery. Complications in the day-case group: Mild vaginal bleeding n=2; one patient readmitted with infected vault haematoma. Complications in the patients that stayed overnight: One patient was admitted with a vault haematoma and one patient was admitted with aspiration pneumonia.

**Conclusion** In suitable patients day-case hysterectomy is safe, with a comparable complication rate to patients admitted overnight, and offers significant cost-savings. There were no adverse outcomes in the first week post-surgery in patients wishing to be discharged home the same day of surgery.

**2022-RA-1395-ESGO** QUALITY ASSESSMENT AS PART OF THE QUALITY ASSURANCE OF A REGIONAL GYNECOLOGICAL COMPREHENSIVE CANCER CARE NETWORK IN THE NETHERLANDS

1Cor D de Kroon, 2Natascha Walpots, 1Ria van Mierlo, 1Maaike vd Aa, 1Brigitte Gispen, 2Anne-Marie den Boer, 1Hans Gelderblom, 1Carina Hilders, 2Marjolein Kagie, 2Obstetrics and Gynaecology, Leiden University Medical Center, Leiden, Netherlands; 2RO West, Leiden, Netherlands; 3Qualicor Europe, Utrecht, Netherlands; 4KNL, Utrecht, Netherlands; 5LUMC, Leiden, Netherlands; 6Reinier de Graaf Gasthuis, Delft, Netherlands; 7Haags Medisch Centrum, The Hague, Netherlands

10.1136/ijgc-2022-ESGO.997

**Introduction/Background** Given the increasing complexity and the volume standards which have become standard practise patients are more frequently treated in so called cancer networks in which different hospitals collaborate intensively. However instruments available for quality assurance are validated for individual hospitals. In the gynaecological cancer network established in our Regional Cancer Network (RO West which consists of 7 hospitals in the Leiden-The Hague area in the Netherlands) we aim to establish network wide quality assurance and consequently adopt well known instruments for usage in networks. In this abstract we report on the quality assessment of the cancer care pathway for ovarian cancer patients in our gynaecological cancer care network.

**Methodology** Indicators with regard to quality of care in cancer networks were extracted from the national Clinical Cancer Network Guidance Book and the national SONCOS standards for oncology and aligned with global Qmentum standards. 5 different fields were covered by 32 standards (organisation/
governance, patient care, research, quality assurance, research and sharing knowledge). Moreover 26 ovarian cancer specific and relevant key pathway and care outcomes indicators were defined. A day was set to visit all 7 hospitals for interviews regarding the indicators with all stakeholders, including patients.

Results All 7 hospitals were visited and relevant stakeholders were interviewed. Network specific indicators were al met, each hospital did not meet different hospital specific indicators, the Dutch Cancer registry was used to get hold of the outcome and pathway indicators and revealed minor differences between the hospitals. Improvement points and action plans were written.

Conclusion Network wide quality assessments, using qualitative and quantitative indicators are feasible and valid as part of the quality assurance program of cancer networks and regional cancer care pathways. Future assessments will be necessary to evaluate to which extent current governance allows alterations for improvement in individual hospitals.

### 2022-RA-1423-ESGO

**PHYLLODES TUMORS OF THE BREAST**

**ANALYSIS OF 17 PATIENTS**

Houda Mochtari. Gynécologie-obstétrique I, CHU Hassan II Fès, Fès, Morocco

10.1136/ijgc-2022-ESGO.998

**Introduction/Background** Phyllode tumors of the breast are fibroepithelial tumors similar to fibroadenomas but with a predominant conjunctive tissue component. These are composed of a connective tissue stroma and epithelial elements. They are rare with an incidence of 0.3–0.9% of all breast neoplasms. The present study demonstrates the recent experiences in diagnosis, therapeutical management and clinical follow-up of this disease.

**Methodology** This is a retrospective study conducted at the obstetrics and gynecology department I at CHU Hassan II in Fez between May 2009 and May 2013, on patients with histologically certified breast phyllodes tumors.

**Results** The patients evaluated were women with an average age of onset of 34.17 years. The mode of revelation was clinical by the discovery of a nodule in 88.24% of cases, mastectomy in 17.64% with one phyllodes sarcoma case (5.9%). The average age of onset of 34.17 years. The mode of revelation was clinical by the discovery of a nodule in 88.24% of cases, mastectomy in 17.64% with one phyllodes sarcoma case (5.9%). The average tumor size is 5.84 cm (0.520 cm). Surgical treatment was conservative in 76.47% (lumpectomy) and radical in 23.53% (mastectomy). Local follow-up in 80% of lost patients. At the end of treatment, 47% operated patients had an unsatisfactory safety margin (recovery of the tumor bed) and 53% patients were in complete clinical remission. After follow-up, 3 patients (17.64%) had one or more relapses with an average interval of 1.4 years (1 year–2 years). No cases of metastasis or deaths were noted.

**Conclusion** The confrontation of our results to the data of the international literature shows that the diagnosis of the phyllodes tumours is histological. The basis of the treatment is surgery. The adjuvant radiotherapy is very important in patients at high risk for local recurrence. The prognostic is based on the histological characters of the tissue conjunctive component of these tumours.